Literature DB >> 7605992

A conserved TATA-less proximal promoter drives basal transcription from the urokinase-type plasminogen activator receptor gene.

E Soravia1, A Grebe, P De Luca, K Helin, T T Suh, J L Degen, F Blasi.   

Abstract

The urokinase-type plasminogen activator receptor (uPAR) focuses at the cell surface the activation of pro-uPA and, hence, the formation of plasmin, thus enhancing directional extracellular proteolysis. To characterize the transcriptional regulatory mechanisms that control receptor expression, we have cloned an uPAR DNA segment containing upstream regulatory sequences from both the human and murine genomes. We report that a proximal promoter, contained within 180 bp from the major transcription start sites of the human uPAR gene, drives basal transcription. This region lacks TATA and CAAT boxes and contains relatively GC-rich proximal sequences. A subregion of this sequence, highly conserved between human and murine genes, contains most of the promoter activity and is specifically bound by HeLa nuclear proteins, one of which belongs to the SP1 class.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7605992

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  12 in total

1.  beta(3)A-integrin downregulates the urokinase-type plasminogen activator receptor (u-PAR) through a PEA3/ets transcriptional silencing element in the u-PAR promoter.

Authors:  S Hapke; M Gawaz; K Dehne; J Köhler; J F Marshall; H Graeff; M Schmitt; U Reuning; E Lengyel
Journal:  Mol Cell Biol       Date:  2001-03       Impact factor: 4.272

2.  Integrin-dependent induction of functional urokinase receptors in primary T lymphocytes.

Authors:  E Bianchi; E Ferrero; F Fazioli; F Mangili; J Wang; J R Bender; F Blasi; R Pardi
Journal:  J Clin Invest       Date:  1996-09-01       Impact factor: 14.808

3.  Transcriptional regulation of urokinase-type plasminogen activator receptor by hypoxia-inducible factor 1 is crucial for invasion of pancreatic and liver cancer.

Authors:  Peter Büchler; Howard A Reber; James S Tomlinson; Oliver Hankinson; Georgis Kallifatidis; Helmut Friess; Ingrid Herr; Oscar J Hines
Journal:  Neoplasia       Date:  2009-02       Impact factor: 5.715

4.  Transgenic mice demonstrate novel promoter regions for tissue-specific expression of the urokinase receptor gene.

Authors:  Heng Wang; John Hicks; Parham Khanbolooki; Sun-Jin Kim; Chunhong Yan; Yao Wang; Douglas Boyd
Journal:  Am J Pathol       Date:  2003-08       Impact factor: 4.307

5.  Urokinase-type plasminogen activator receptor transcriptionally controlled adenoviruses eradicate pancreatic tumors and liver metastasis in mouse models.

Authors:  Meritxell Huch; Alena Gros; Anabel José; Juan Ramon González; Ramon Alemany; Cristina Fillat
Journal:  Neoplasia       Date:  2009-06       Impact factor: 5.715

6.  PLAUR polymorphisms and lung function in UK smokers.

Authors:  Ceri E Stewart; Ian P Hall; Stuart G Parker; Miriam F Moffat; Andrew J Wardlaw; Martin J Connolly; Charlotte Ruse; Ian Sayers
Journal:  BMC Med Genet       Date:  2009-10-31       Impact factor: 2.103

7.  Characterisation of urokinase plasminogen activator receptor variants in human airway and peripheral cells.

Authors:  Ceri E Stewart; Ian Sayers
Journal:  BMC Mol Biol       Date:  2009-07-28       Impact factor: 2.946

8.  The prognostic value of the suPARnostic ELISA in HIV-1 infected individuals is not affected by uPAR promoter polymorphisms.

Authors:  Uffe V Schneider; Rikke L Nielsen; Court Pedersen; Jesper Eugen-Olsen
Journal:  BMC Infect Dis       Date:  2007-11-16       Impact factor: 3.090

9.  AduPARE1A and gemcitabine combined treatment trigger synergistic antitumor effects in pancreatic cancer through NF-κB mediated uPAR activation.

Authors:  Maria Victoria Maliandi; Ana Mato-Berciano; Luciano Sobrevals; Gaël Roué; Anabel José; Cristina Fillat
Journal:  Mol Cancer       Date:  2015-07-31       Impact factor: 27.401

10.  Transforming growth factor-Beta and urokinase-type plasminogen activator: dangerous partners in tumorigenesis-implications in skin cancer.

Authors:  Juan F Santibanez
Journal:  ISRN Dermatol       Date:  2013-07-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.